#SFHS2613281AFrance Expands Reimbursement for Pediatric Uses of Apremilast and Mycophenolate Mofetil
AI-generated summary for informational purposes only. Not legal advice. See the original source for the authoritative text.
This order expands French social security reimbursement for specific medicines used in children and adolescents. Apremilast HCS is now covered for moderate to severe plaque psoriasis in patients aged 6 and over who weigh at least 20 kg and need systemic treatment. It also expands coverage for Mycophenolate Mofetil Mylan and Mycophenolate Mofetil Viatris when used with ciclosporin and corticosteroids to prevent acute organ rejection in certain pediatric transplant patients. For those transplant indications, the patient co-payment is removed, reducing out-of-pocket costs for eligible families.
AI-generated summary. May contain errors. Refer to official sources for legal decisions.
Key Changes
- Extends reimbursement for Apremilast HCS to moderate to severe plaque psoriasis in children and adolescents aged 6 and over who weigh at least 20 kg and need systemic treatment.
- Extends reimbursement for Mycophenolate Mofetil Mylan and Viatris for prevention of acute organ rejection in specified pediatric kidney, heart, and liver transplant patients.
- Removes the patient co-payment for the listed pediatric transplant indications.
Obligations
What this law requires
Extend social security reimbursement coverage for APREMILAST HCS 10 mg/20 mg/30 mg initiation pack and APREMILAST HCS 30 mg tablets to treatment of moderate to severe plaque psoriasis in children and adolescents aged 6 years or older, weighing at least 20 kg, who require systemic treatment.
Extend reimbursement coverage for MYCOPHENOLATE MOFETIL MYLAN 500 mg tablets and MYCOPHENOLATE MOFETIL VIATRIS 500 mg tablets, when used with ciclosporin and corticosteroids, for prevention of acute organ rejection in pediatric renal allograft patients aged 1 to 2 years.
Extend reimbursement coverage for MYCOPHENOLATE MOFETIL MYLAN 500 mg tablets and MYCOPHENOLATE MOFETIL VIATRIS 500 mg tablets, when used with ciclosporin and corticosteroids, for prevention of acute organ rejection in pediatric heart or liver allograft patients aged 1 to 18 years.
Remove the insured patient co-payment for MYCOPHENOLATE MOFETIL MYLAN and MYCOPHENOLATE MOFETIL VIATRIS when prescribed for the covered pediatric transplant rejection-prevention indications listed in the order.